We have examined whether active immunization with c13 protein, a hybrid protein of the first 81 amino acids of the viral NS1 nonstructural protein and the HA2 subunit of A/PR/8 (H1N1) hemagglutinin, could protect BALB/c mice from challenge with A/PR/8 H1 subtype virus. Mice immunized with the c13 protein had a significant reduction of pulmonary virus titers with A/PR/8 (H1) virus, but failed to limit the replication of A/PC (H3) virus, which reflects the in vitro CTL activity of c13 immune spleen cells. We observed that the epitope recognized by HA2 specific CTL, which are induced by a derivative of c13 protein, is highly conserved among H1 and H2 subtype virus strains. This led us to test whether active immunization with c13 protein would also limit pulmonary virus replication in mice infected with the A/TW virus, a virus of the H1 subtype, which was isolated in 1986, and with a virus of the H2 subtype, A/Japan/305/57. Immunized mice had significantly lower lung virus titers than did control mice, and did not possess any neutralizing antibodies to the challenger viruses. These results indicate that active immunization with a fusion protein containing the cross-reactive CTL epitope protects mice from influenza infection by inducing CTL against influenza A H1 and H2 subtype virus strains, which markedly vary in their antibody binding sites on the HA1. The ability to induce active cross-reactive immunization with a fusion protein which contains a highly conserved CTL epitope offers a model for vaccine approaches against viruses which undergo significant variations in their antibody binding sites.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189225 | PMC |
http://dx.doi.org/10.1084/jem.169.4.1361 | DOI Listing |
Gac Sanit
March 2025
Financial Economics and Accounting Department, University of Alicante, Alicante, Spain.
Objective: To review several behavioral economics-based interventions ("healthy nudges") aimed at mitigating the overuse and underuse of healthcare resources -phenomena associated with poorer health outcomes and increased costs.
Method: A comparative case study approach is used to assess the effectiveness of ten studies designed to improve treatment adherence and prevent underuse, as well as those focused on improving prescribing practices to address overuse.
Results: First, healthy nudges are generally effective, although there is considerable variability in their outcomes.
Vaccine
March 2025
Robert Koch Institute, Am Nordufer 20, 13353 Berlin, Germany. Electronic address:
Introduction: As of 24 October 2021, 128,868 laboratory-confirmed COVID-19 cases and 3550 deaths were reported from Namibia. The national COVID-19 vaccination campaign that started in March 2021 included health workers (HWs) as a priority group. The vaccines most administered were Sinopharm, AstraZeneca, Pfizer-BioNtech, and Janssen.
View Article and Find Full Text PDFAm J Obstet Gynecol
March 2025
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Department of Infectious Diseases, Singapore General Hospital, Singapore. Electronic address:
Background: Significant heterogeneity has been reported in estimates of long-term sequelae following SARS-CoV-2 infection in pregnant women, and most studies were conducted pre-Omicron and pre-dated vaccination rollout. Less severe COVID-19 attributed to milder Omicron may potentially attenuate risk of post-COVID-19 sequelae.
Objective: We sought to examine long-term risk of new-incident multi-systemic sequelae following SARS-CoV-2 Delta/Omicron infection in a population-based cohort of pregnant women, contrasted against a)test-negatives; b)infected non-pregnant women of childbearing age.
Value Health Reg Issues
March 2025
Division of Pulmonary Medicine, UP Manila College of Medicine and Philippine General Hospital, Ermita, Manila, Philippines.
Objectives: The Philippine National Immunization Program guidelines recommend using the 23-valent pneumococcal polysaccharide vaccine (PPV23) among senior citizens. We conducted cost-effectiveness analyses to assess the impact of replacing 2-dose PPV23 with PCV13 in all adults aged ≥60 years and expanding the recommendation to include PCV13 for adults aged 18 to 59 years at elevated risk of disease (moderate-/high-risk).
Methods: Lifetime risks and costs of invasive pneumococcal disease, nonbacteremic pneumococcal pneumonia (NBPP), and expected impact of vaccination were projected using a probabilistic cohort model.
Vaccine
March 2025
Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Background: To generate COVID-19 vaccine safety data in Nigeria, passive reporting was supplemented with cohort event monitoring (CEM), an active surveillance system. We described reactogenicity within 7 days and adverse events up to 3 months after each AstraZeneca or Moderna COVID-19 vaccine dose while assessing the feasibility of implementing CEM in a low- to middle-income country (LMIC) during a mass vaccination campaign.
Methods: Participants were aged ≥18 years with access to mobile phones who received the first dose of an authorized COVID-19 vaccine from participating health facilities in 6 states of Nigeria during September and October 2021.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!